GLOBAL MARKET ACCESS STRATEGY
Senior strategic counsel for pharmaceutical and biotechnology leaders connecting asset ambition, payer requirements, evidence and launch execution across priority markets.
THE STRATEGIC QUESTION
Market access strategy is most valuable when it shapes decisions early. VELA helps teams identify the access conditions that matter, expose critical uncertainties and turn complex market evidence into a focused path forward.
HOW WE CAN HELP
VELA supports pharmaceutical and biotechnology companies in developing global market access strategies from early clinical development through launch and lifecycle management.
Our approach connects asset positioning, payer expectations, evidence requirements and market dynamics to define strategic priorities, identify critical decisions and establish actionable access roadmaps.
Understanding payer expectations early is essential to shaping an effective market access strategy.
VELA helps translate payer needs, reimbursement considerations, health technology assessment (HTA) requirements and market-specific access barriers into strategic implications for asset development, evidence planning and value positioning.
Successful market access requires alignment between clinical development, evidence generation, pricing strategy and launch execution.
VELA supports market prioritization, indication sequencing, access readiness assessments and strategic planning to help biopharma teams anticipate challenges, identify dependencies and prepare for critical launch decisions.
Complex market access decisions require coordinated perspectives across clinical development, medical affairs, HEOR, pricing and commercial functions.
VELA provides independent senior-level strategic counsel to facilitate cross-functional alignment, clarify trade-offs and support informed decision-making at key development and commercialization milestones.
DELIVERABLES
Strategic clarity. Actionable recommendations. Decision-ready deliverables.
Each engagement is tailored to the asset, development stage and strategic priorities of the client. Depending on project scope, deliverables may include:
An integrated framework identifying access priorities, key decisions, evidence dependencies and strategic milestones across the asset lifecycle.
A structured assessment of existing and planned evidence against payer and HTA expectations, highlighting critical uncertainties and opportunities for evidence planning.
Strategic evaluation of priority markets considering access requirements, reimbursement environments, evidence expectations and launch considerations.
Focused recommendations to support cross-functional preparedness, identify potential access barriers and strengthen launch planning.
Our commitment: Senior-level expertise, independent strategic perspective and practical recommendations designed to support confident decision-making.
WHEN TO ENGAGE
START A CONVERSATION
Whether you are shaping an early asset strategy, preparing for launch or navigating complex payer and evidence requirements, VELA brings focused senior-level expertise to the decisions that matter.
Discuss Your Access Challenge ↗Connect with VELA Access Partners to explore how tailored strategic support can help your team move forward.